December 28, 2001 - Connectics Corporation, a publicly held
biopharmaceutical company, is currently developing a new hair
loss product based on Minoxidil, the active ingredient in Rogaine.
new Minoxidil product is based on a proprietary foam delivery
vehicle manufactured by Connectics that currently has two
products on the market using this technology. The two innovative
foam-based products on the market are for the treatment of
scalp dermatoses: Luxíq, a mid-potency steroid, and
OLUX, a super high-potency steroid.
to Connectics their proprietary foam delivery system has significant
treatment, cosmetic and functional advantages over conventional
delivery systems. These advantages include improved efficacy
due to higher absorption and more localized delivery of the
active agent. The unique foam formulation liquefies when applied
to the skin, and enables rapid penetration of the active dermatologic
agent, thus enhancing efficacy.
is currently applying this foam technology to create a new
Minoxidil foam for treating hair loss. This should offer superior
results over the existing Minoxidil products which typically
use a Propylene Glycol/ethanol/water vehicle. The more efficient
the vehicle, the better the penetration of the drug through
the skin and the better the results will be. It is unclear
at this time exactly how much better the results will be.
product of interest to hair loss sufferers being developed
by Connectics is Relaxin. Relaxin is a naturally occurring
hormone with several distinct biological activities including
vasodilation, angiogenesis, and inhibition of fibrosis. The
hormone is thought to be responsible for many cardiovascular
changes that occur during pregnancy, including increased blood
flow, which is due to an increase in the number of vessels
(angiogenesis) and an expansion in the diameter of vessels
(dilation). The site-specific angiogenic effects are mediated
by local upregulation of bFGF and VEGF by relaxin, and the
vasodilatory effects are thought to be mediated by inhibiting
the constrictive effects of angiotensin and endothelin.
is not being developed for hair loss, but may have some beneficial
results when used as part of a hair loss treatment regime.
In people with medium to long term hair loss there is usually
fibrosis of the follicle and loss of scalp vascularization
that limits the full recovery of the follicles when using
treatments like Rogaine.
is focused on developing products for specialty medical markets,
which are characterized by diseases that are primarily treated
by a concentrated physician base of dermatologists. Connetics'
goal is to develop and market innovative pharmaceutical products
that may ease suffering of and give new hope for patient groups
that are underserved and without treatment for their afflictions.
also have several other products in development including
an antifungal foam for fungal diseases, an antibiotic foam
for acne and a retinoid Liquipatch for acne. The company currently
employs approximately 152 people, 71 of them in their Palo
Alto, California office. Included in this number are 11 employees
in their Australian based company, Soltec, and 70 US field
based sales employees.